ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2393

Improving Clinical Outcomes In SLE Arthritis Trials: Post-Hoc Analysis Of A Prospective Intervention Study
Abstract Number: 2394

Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Abstract Number: 2395

Analysis of histopathological changes in the placenta of patients with systemic lupus erythematosus
Abstract Number: 2396

A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
Abstract Number: 2397

Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Abstract Number: 2398

Analytical performance of the HEp-2 substrate Diagnostic Kit for ANA as an initial step in the evaluation of a novel Fully Automated IFA Analyzer in a laboratory in England
Abstract Number: 2399

Identification of an LN endotype linked to intestinal expansion of Pathogenic Strains of a Pathobiont Bacterium that induces Systemic Thrombo-inflammatory Pathways directly measurable in Urine
Abstract Number: 2400

Prevalence and Predictors of Types and Subtypes of Pulmonary Diseases in Systemic Lupus Erythematosus: A Population-Based Cross-Sectional Study Using High-Resolution Computed Tomography Scan and Pulmonary Function Testing
Abstract Number: 2401

Associations between Serum Levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) and Activity and Chronicity Features in Diagnostic and Per-Protocol Repeat Kidney Biopsies in Patients with Lupus Nephritis
Abstract Number: 2402

High-Resolution Proteomic Profiling Validates BAFF Pathway Modulation and Reveals Novel Biomarker Signatures in Belimumab Treatment
Abstract Number: 2403

Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Abstract Number: 2404

Clinical features of Elderly-onset Systemic Lupus Erythematosus
Abstract Number: 2405

Machine Learning in SLE Diagnosis: Performance of the SLE Risk Probability Index Questionnaire in a Multicenter Cohort of Patients with Systemic Lupus Erythematosus
Abstract Number: 2406

Machine Learning-Based Artificial Intelligence in Systemic Lupus Erythematosus: A Systematic Review of Outcome Prediction and Patient Stratification
Abstract Number: 2407

Mapping Neurological Involvement, Regional Disparities, and Moderators of the Central Nervous System in Adult-Onset Systemic Lupus Erythematosus: A Global Systematic Review and Meta-Analysis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].